Mesoblast Limited

MSB

AU000000MSB8

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 07:10:09 18/07/2024 BST			5-day change	1st Jan Change
1.105 ^AUD	-1.78%		0.00%	+256.45%

07-10	Mesoblast Limited Resources Biologics Licence Application with United States Food & Drug Administration for Approval of Ryoncil in the Treatment of Children with SR-aGVHD	CI
07-09	Mesoblast Resubmits Ryoncil Biologics License Application	MT

Mesoblast limited : 11 January 2013 - Mesoblast’s NeoFuse Stem Cell Product Shows Positive Results in Phase 2 Lumbar Spinal Fusion Trial; Results Support Progression of Clinical Development to Phase 3

January 11, 2013 at 03:28 am

MarketScreener.com By

MESOBLAST'S NEOFUSE STEM CELL PRODUCT SHOWS POSITIVE RESULTS IN PHASE 2 LUMBAR SPINAL FUSION TRIAL Results support progression of clinical development to Phase 3 Key points:

Latest news about Mesoblast Limited

Mesoblast Limited Resources Biologics Licence Application with United States Food & Drug Administration for Approval of Ryoncil in the Treatment of Children with SR-aGVHD	07-10	CI
Mesoblast Resubmits Ryoncil Biologics License Application	07-09	MT
Mesoblast Refiles Biological License Application with the Us FDA for Cell Therapy; Shares Fall 6%	07-09	MT
Mesoblast to File Biological License Application with US FDA for Cellular Therapy	07-02	MT
Mesoblast to File Biologics License Application for Ryoncil	07-01	MT
Mesoblast to File Biologics License Application for Ryoncil FDA Approval Next Week	07-01	CI
Mesoblast Limited Announces Board and Committee Changes	05-01	CI
ADRs End Higher; Connect Biopharma Climbs 26%	04-01	DJ
ADRs End Lower; NuCana Slides 15%	03-28	DJ
ADRs End Lower; Quhuo Drops 53%	03-26	DJ
FDA Says Mesoblast Trial Data Sufficient to Support BLA Submission	03-26	MT
Sector Update: Health Care Stocks Advance Late Afternoon	03-26	MT
Top Midday Gainers	03-26	MT
Sector Update: Health Care Stocks Steady Premarket Tuesday	03-26	MT
Wall Street Set to Open Modestly Higher Tuesday Ahead Consumer Confidence Reading	03-26	MT
Top Premarket Gainers	03-26	MT
Mesoblast Shares Jump After FDA Nod for Submission of Remestemcel-L Application	03-26	DJ
Mesoblast to Resubmit Application for Potential Pediatric Treatment of Graft Versus Host Disease; Shares Gain Pre-Bell	03-26	MT
United States Food & Drug Administration Notifies Mesoblast Limited of Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease	03-26	CI
Mesoblast Limited(ASX:MSB) added to S&P/ASX Emerging Companies Index	03-17	CI
Mesoblast Raises AU$97 Million From Entitlement Offer, Institutional Placement	03-14	MT
Mesoblast Raises AU$97 Million for Phase Three Registration Trials	03-14	MT
Sector Update: Health Care Stocks Softer Late Afternoon	03-11	MT
Sector Update: Health Care Stocks Decline in Afternoon Trading	03-11	MT
Sector Update: Health Care	03-11	MT

Mesoblast Limited is an Australia-based company, which is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. It has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. It is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for advanced chronic heart failure (REVASCOR) and chronic low back pain (MPC-06-ID). Two products have been commercialized in Japan and Europe by the Company's licensees. It has established commercial partnerships in Europe and China for certain Phase III assets.

Sector

Biotechnology & Medical Research

Calendar

27/08/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Mesoblast Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.125 AUD

Average target price

1.25 AUD

Spread / Average Target

+11.11%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MESOBLAST LIMITED	+256.45%	864M
MODERNA, INC.	+24.74%	47.54B
IQVIA HOLDINGS INC.	-0.47%	41.96B
LONZA GROUP AG	+49.45%	41.55B
ALNYLAM PHARMACEUTICALS, INC.	+25.40%	30.36B
CELLTRION, INC.	-4.47%	28.7B
ICON PUBLIC LIMITED COMPANY	+17.96%	27.61B
UNITED THERAPEUTICS CORPORATION	+50.73%	14.7B
MEDPACE HOLDINGS, INC.	+42.56%	13.51B
BIO-TECHNE CORPORATION	+1.46%	12.34B

Other Biotechnology & Medical Research